US OptionsDetailed Quotes
SLS241220C500
- 0.75
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
0.75Open0.75Pre Close0 Volume6 Open Interest0.50Strike Price0.00Turnover0.00%IV6.84%PremiumDec 20, 2024Expiry Date0.67Intrinsic Value100Multiplier28DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.87Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sellas Life Sciences Stock Discussion
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group (NASDAQ: SLS) has received Rare Pediatric Disease Designation (RPDD) from the FDA for Galinpepimut-S (GPS) in treating pediatric acute myeloid leukemia (AML). GPS, an immunotherapeutic targeting Wilms Tumor-1, is currently in a Phase 3 REGAL trial for adult AML patients, with an inte...
Sellas Receives EMA Orphan Drug Designation for Sls009 for Treatment of Peripheral T-Cell Lymphomas
No comment yet